Zim Laboratories financials

·Pharma & HealthChart ›
Latest results Q1 FY27 · Apr–Jun 2026
Revenue
₹94.2cr+31.2% on Q1 FY26
Net profit
−₹4.0cr−₹1.9 cr in Q1 FY26
EBITDA margin
2.6%−3.3 pts on Q1 FY26
EPS
−₹0.75−₹0.38 in Q1 FY26

Quarterly results

Every quarter ›
₹ croreQ1 FY27Q1 FY26Change
Revenue94.271.8+31.2%
EBITDA2.54.3−42.5%
EBITDA margin2.6%5.9%−3.3 pts
Profit before tax−5.6−2.4—
Net profit−4.0−1.9—
EPS−₹0.75−₹0.38—

Over time

Q1 FY27 · Apr–Jun 2026latest
Revenue₹94.2 crNet profit₹−4.0 crNet margin−4.3%

Amounts on the left scale in ₹ crore; per cent on the right, dashed. L = lakh crore, K = thousand crore. Touch the chart to read any period.

Key numbersby financial year

₹ crore except per share
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023
756————
25.125.11.99.66.4
0.00.00.00.00.0
12312311210659.6
854————
397374379367399
—−1.2%+3.2%−7.8%—
28.230.043.741.352.0
7.1%8.0%11.5%11.3%13.0%
7.710.023.625.434.5
3.75.812.217.224.4
0.9%1.6%3.2%4.7%6.1%
₹0.69₹1.09₹2.27₹3.22₹4.57
—−52.0%−29.5%−29.4%—
—49.541.216.337.5
—−44.4−40.8−73.9−36.7
5.15.10.4−57.60.9
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ZIMLAB₹141.26

Zim Laboratories Limited

· Pharma & Health
₹ CrorePeersANUHPHRVALIANTLABAHCLALBERTDAVDWANBURYHALEOSLABSBAJAJHCARETHEMISMEDMcap ₹756 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
In ₹ Crore except Per Share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Market Capitalization————755.7
- Cash, Equiv & ST Investments6.49.61.925.125.1
+ Minority Interest0.00.00.00.00.0
+ Total Debt59.6106.4112.2123.0123.0
Enterprise Value————853.6
Revenue398.5367.4379.0374.4396.8
Growth %, YoY—-7.8+3.2-1.2—
EBITDA52.041.343.730.028.2
Margin %13.0411.2511.548.027.11
EBIT34.525.423.610.07.7
Net Income24.417.212.25.83.7
Margin %6.134.693.211.560.93
EPS, Adj (current shares)4.573.222.271.090.69
Growth %, YoY—-29.4-29.5-52.0—
Cash from Operations37.516.341.249.5—
Capital Expenditures-36.7-73.9-40.8-44.4—
Free Cash Flow0.9-57.60.45.15.1
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Zim Laboratories financials and key ratios

Prices at the 29 October 2026 close · figures from the company's filings with NSE

Zim Laboratories (NSE: ZIMLAB) had a market capitalisation of ₹731 crore at the 29 October 2026 close (₹136.54 a share), a PE ratio of 197.8 on the last four quarters' profit and a price-to-book ratio of 2.47. In FY26 its consolidated net profit was ₹5.8 crore on revenue of ₹374 crore; in Q1 FY27 (April–June 2026) it was a loss of ₹4 crore. Its debt-to-equity ratio was 0.42 on 31 March 2026. Promoters held 30.30% of the shares on 30 September 2026.

Share price used
₹136.54 · 29 October 2026 close
Latest balance sheet
31 March 2026
Shareholding pattern
30 September 2026

Zim Laboratories at a glance · consolidated

Market cap
₹731 Crat ₹136.54 · 29 Oct close
PE ratio (last 4 quarters)
197.8125.2 on FY26 profit
Price to book (PB)
2.47book value ₹55.31 a share
ROE (FY26)
2.1%−2.8 pts vs FY25ROCE 3.1%
Debt to equity
0.42net debt ₹79.6 Cr
Promoter holding
30.30%−0.1 pts vs 30 Jun 202630 September 2026
Net worth
₹296 Cr+17.4% vs 31 Mar 202531 March 2026
Free cash flow (FY26)
₹5.1 Cr
EPS (FY26)
₹1.19

Questions

What is the Zim Laboratories PE ratio today?

Zim Laboratories' PE ratio is 197.8 at the 29 October 2026 close (₹136.54 a share): a market capitalisation of ₹731 crore divided by consolidated net profit of ₹3.7 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹5.8 crore) it is 125.2.

What is the Zim Laboratories debt to equity ratio?

Zim Laboratories' debt-to-equity ratio was 0.42 on 31 March 2026: borrowings of ₹123 crore against total equity of ₹296 crore. A year earlier, on 31 March 2025, it was 0.44.

What is the Zim Laboratories net worth?

Zim Laboratories' net worth — shareholders' equity in its consolidated balance sheet — was ₹296 crore on 31 March 2026, up 17.4% from ₹252 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹731 crore at the 29 October 2026 close.

What is the Zim Laboratories PB ratio (price to book value)?

Zim Laboratories' price-to-book (PB) ratio is 2.47 at the 29 October 2026 close: a market capitalisation of ₹731 crore divided by shareholders' equity (book value) of ₹296 crore on 31 March 2026. That is a book value of ₹55.31 per share against a share price of ₹136.54.

What is the Zim Laboratories ROE and ROCE?

In FY26, Zim Laboratories' return on equity (ROE) was 2.1% and its return on capital employed (ROCE) was 3.1%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 5.0% and ROCE 8.0%.

What is the Zim Laboratories book value per share?

Zim Laboratories' book value per share was ₹55.31 on 31 March 2026: shareholders' equity of ₹296 crore divided by the 5.35 crore shares in issue, up 6.8% from ₹51.77 a year earlier. The share price at the 29 October 2026 close was ₹136.54.

What is the Zim Laboratories market cap?

Zim Laboratories' market capitalisation was ₹731 crore at the 29 October 2026 close: 5.35 crore shares at ₹136.54 each.

Is Zim Laboratories debt free?

No. Zim Laboratories had borrowings of ₹123 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.42. Its cash and current investments were ₹43.4 crore, so its net debt was ₹79.6 crore.

What is the Zim Laboratories EPS?

Zim Laboratories' basic earnings per share (EPS) were ₹1.19 in FY26, against ₹2.50 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹0.82.

What is the Zim Laboratories promoter holding?

Promoters held 30.30% of Zim Laboratories on 30 September 2026, down 0.06 percentage points from 30.36% the previous quarter and down 2.96 percentage points from 33.26% a year earlier, according to the shareholding pattern filed with NSE.

What is the Zim Laboratories free cash flow?

In FY26, Zim Laboratories generated ₹49.5 crore of cash from operations and spent ₹44.4 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹5.1 crore. In FY25 it was ₹36 lakh.

What are the Zim Laboratories latest quarterly results?

Zim Laboratories' latest results are for Q1 FY27 (April–June 2026), filed on 6 August 2026: consolidated net loss ₹4 crore, wider than the loss of ₹1.9 crore in Q1 FY26; revenue from operations ₹94.2 crore, up 31.2% year on year.

What is the Zim Laboratories shareholding pattern?

On 30 September 2026, Zim Laboratories' shares were held by promoters 30.30%, foreign portfolio investors (FII/FPI) 0.17%, domestic institutions (DII) 1.19% (including mutual funds at 1.18%) and retail and other non-institutional investors 68.34%. Over the year, DII holding was up 0.95 percentage points from 0.24%.

What is the Zim Laboratories revenue and profit in FY26?

In FY26 (April 2025–March 2026), Zim Laboratories' consolidated net profit was ₹5.8 crore, down 52.0% from ₹12.2 crore in FY25, on revenue from operations of ₹374 crore (down 1.2%). Over three years, from FY23, net profit was down 76.1%.

How does Zim Laboratories compare with its peers?

On FY26 consolidated figures, against Anuh Pharma, Valiant Laboratories and Anlon Healthcare: Zim Laboratories' operating margin of 2.7% is the third highest of the four (Anuh Pharma 6.5%, Valiant Laboratories 0.2%, Anlon Healthcare 26.8%; peer average 11.1%); its return on equity of 2.1% is the third highest of the four (Anuh Pharma 12.1%, Valiant Laboratories −1.2%, Anlon Healthcare 12.4%; peer average 7.8%).

When are the Zim Laboratories next results?

Zim Laboratories will announce its Q2 FY27 results (July–September 2026) on Wednesday, 4 November 2026, the date of the board meeting it has notified to the exchanges.

Zim Laboratories vs Anuh Pharma: how do they compare?

In FY26, Zim Laboratories earned net profit of ₹5.8 crore on revenue of ₹374 crore, against ₹41 crore on ₹772 crore for Anuh Pharma. Zim Laboratories' operating margin was 2.7% (Anuh Pharma 6.5%) and its return on equity 2.1% (Anuh Pharma 12.1%). At the 29 October 2026 close, Zim Laboratories' market capitalisation was ₹731 crore against ₹799 crore for Anuh Pharma, and its PE ratio on FY26 profit 125.2 against 19.5.

Where do these Zim Laboratories figures come from?

From Zim Laboratories' own consolidated results, balance sheets and shareholding patterns filed with NSE, and NSE prices (the latest used here: the 29 October 2026 close). Ratios are calculated by Alphave from those filings as each answer describes.

Consolidated figures from the company's filings with NSE; prices are NSE closing prices.